Home » Authors » Jim Shrine

Articles by Jim Shrine

NeurogesX Presents Positive Data From Trial Of Pain Patch

Nov. 1, 2011

No Abstract

NewCo News: Aileron Raises $7M For Work On Peptide Technology Platform

Nov. 1, 2011

No Abstract

KineMed Applying Translation Technologies In Deal With Bayer

Nov. 1, 2011

No Abstract

Renovis Cuts Staff As Focus Moves To Preclinical Programs

Nov. 1, 2011

No Abstract

Santhera Starts Phase III Trial In Friedreich's Ataxia Patients

Oct. 1, 2007

Santhera Starts Phase III Trial In Friedreich's Ataxia Patients

Oct. 1, 2007

NPS, Nycomed Enter Potential $185M Deal Covering Gattex

Sep. 27, 2007

NPS, Nycomed Enter Potential $185M Deal Covering Gattex

Sep. 27, 2007

Sonus Crashes On Failed Pivotal Trial Of Tocosol Paclitaxel Drug

Sep. 25, 2007

Sonus Crashes On Failed Pivotal Trial Of Tocosol Paclitaxel Drug

Sep. 25, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...